Leflunomide and Teriflunomide interaction

Leflunomide and Teriflunomide: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Leflunomide (Arava) label · effective 2025-06-04

Major

Patients being treated with teriflunomide [see Drug Interactions (7) ] .

Contraindicationsnames TeriflunomideView label on DailyMed
Major

Current teriflunomide treatment.

Contraindicationsnames TeriflunomideView label on DailyMed
Moderate

After stopping ARAVA, it is recommended that an accelerated drug elimination procedure be used to reduce the plasma concentrations of the active metabolite, teriflunomide.

Warnings and precautionsnames TeriflunomideView label on DailyMed
Moderate

If a woman becomes pregnant while taking ARAVA, stop treatment with ARAVA, apprise the patient of the potential risk to a fetus, and perform an accelerated drug elimination procedure to achieve nondetectable plasma concentrations of teriflunomide, the active metabolite of leflunomide [see Warnings and Precautions (5.3) ] .

Warnings and precautionsnames TeriflunomideView label on DailyMed
Moderate

Based on animal data, human plasma concentrations of teriflunomide of less than 0.02 mg/L (0.02 mcg/mL) are expected to have minimal embryo-fetal risk [see Contraindications (4) , Warnings and Precautions (5.3) , and Use in Specific Populations (8.1) ] .

Warnings and precautionsnames TeriflunomideView label on DailyMed

From the Teriflunomide (Aubagio) label · effective 2026-02-20

Major

Current leflunomide treatment ( 4 )

Contraindicationsnames LeflunomideView label on DailyMed
Major

Patients with a history of a hypersensitivity reaction to teriflunomide, leflunomide, or to any of the inactive ingredients in AUBAGIO.

Contraindicationsnames LeflunomideView label on DailyMed
Major

Coadministration with leflunomide [see Clinical Pharmacology (12.3) ].

Contraindicationsnames LeflunomideView label on DailyMed
Major

Fatal infections have been reported in the postmarketing setting in patients receiving leflunomide, especially Pneumocystis jirovecii pneumonia and aspergillosis.

Warnings and precautionsnames LeflunomideView label on DailyMed
Minor

No cases of serious pancytopenia were reported in premarketing clinical trials of AUBAGIO but rare cases of pancytopenia and agranulocytosis have been reported in the postmarketing setting with leflunomide.

Warnings and precautionsnames LeflunomideView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.